Revenue for the quarter increased by 35.2% from the same quarter last year to ₹1,653 crore, which is higher than the CNBC-TV18 poll expectation of ₹1,553.1 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter increased by 126% to ₹403 crore. A CNBC-TV18 poll had projected the figure to be ₹368.3 crore.
EBITDA margin for the quarter expanded by more than 1,000 basis points from last year to 24.4%, higher compared to the CNBC-TV18 poll projection of 23.7%. This is the fourth straight quarter that Laurus Labs has reported EBITDA margin in excess of 20%.
Net profit for the period stood at ₹195 crore, while the CNBC-TV18 poll had projected the figure to be ₹147 crore. Laurus Labs had reported a net profit of ₹20 crore in the base quarter.
On Monday, brokerage firm B&K Securities had initiated coverage on Laurus Labs with a "buy" rating and a price target of ₹1,030. The firm said that Laurus Labs is entering a strong growth cycle led by its high-margin CDMO business, which has gradually emerged as the company's key earnings driver.
Shares of Laurus Labs are trading 0.9% higher at ₹932.4. The stock trades close to its record high level of ₹944. Shares of gained 51% so far on a year-to-date basis.
/images/ppid_59c68470-image-176121252677216192.webp)

/images/ppid_59c68470-image-176114753103515793.webp)
/images/ppid_59c68470-image-176119502886941900.webp)
/images/ppid_59c68470-image-176120012674681132.webp)
/images/ppid_59c68470-image-176120258247090480.webp)
/images/ppid_59c68470-image-176120752684263474.webp)
/images/ppid_59c68470-image-176120002666494070.webp)
/images/ppid_59c68470-image-176121255840418111.webp)
/images/ppid_59c68470-image-176103257503486935.webp)
/images/ppid_59c68470-image-176093517598795442.webp)
/images/ppid_59c68470-image-176104008964323540.webp)